Skip to Content
Merck
All Photos(1)

Key Documents

A1287

Sigma-Aldrich

5-Azacytidine

Hybri-Max, γ-irradiated, lyophilized powder, BioXtra, suitable for hybridoma

Synonym(s):

4-Amino-1-(β-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one, Ladakamycin

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C8H12N4O5
CAS Number:
Molecular Weight:
244.20
Beilstein:
620461
EC Number:
MDL number:
UNSPSC Code:
12352207
PubChem Substance ID:
NACRES:
NA.75

biological source

synthetic (organic)

Quality Level

grade

Hybri-Max

sterility

γ-irradiated

product line

BioXtra

form

lyophilized powder

technique(s)

cell culture | hybridoma: suitable

impurities

endotoxin, tested

mp

226-232 °C (dec.) (lit.)

solubility

acetic acid: water (1:1): 5 mg/mL, clear, colorless

antibiotic activity spectrum

viruses

Mode of action

DNA synthesis | interferes

storage temp.

−20°C

SMILES string

NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O

InChI

1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1

InChI key

NMUSYJAQQFHJEW-KVTDHHQDSA-N

Gene Information

Looking for similar products? Visit Product Comparison Guide

General description

Chemical structure: nucleoside

Application

5-Azacytidine may be used to induce in vitro cardiomyogenic differentiation of adult human bone marrow mesenchymal stem cells. It may also be used to study the effects of 5-Azacytidine on the immune regulatory myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs).
Used to study the effects of the DNA incorporated molecule on DNA methylation processes.

Biochem/physiol Actions

5-Azacytidine is a deoxycytidine analog and a demethylating agent. It acts as a potential antineoplastic agent for acute myelogenous leukemia. 5-Azacytidine activates repressed genes by inhibiting DNA methylation. 5-Azacytidine also affects protein synthesis by altering the RNA function and stability.
A potent growth inhibitor and cytotoxic agent; inhibits DNA methyltransferase, an important regulatory mechanism of gene expression, gene activation and silencing.

Reconstitution

Reconstitute contents of vial with 10 mL sterile cell culture medium. Stock solution is sufficient to prepare 500ml medium. Final working concentration: 10 μM 5-azacytidine.

Legal Information

Hybri-Max is a trademark of Sigma-Aldrich Co. LLC

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 1 - Carc. 1A - Muta. 2 - Repr. 1B - STOT RE 1

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

DNA methyltransferase inhibitors for cancer therapy
Epigenetics, 5(3), 265-290 (2015)
5-azacytidine treatment reorganizes genomic histone modification patterns
Komashko VM and Farnham PJ
Epigenetics, 5(3), 229-240 (2010)
Manuel Luís Orta et al.
Nucleic acids research, 41(11), 5827-5836 (2013-04-24)
5-Aza-2'-deoxycytidine (5-azadC) is a DNA methyltransferase (DNMT) inhibitor increasingly used in treatments of hematological diseases and works by being incorporated into DNA and trapping DNMT. It is unclear what DNA lesions are caused by 5-azadC and if such are substrates
L H van der Helm et al.
Leukemia research, 37(8), 877-882 (2013-05-01)
The efficacy of azacitidine has been demonstrated in acute myeloid leukemia (AML) patients with 20-30% bone marrow (BM) blasts, but limited data is available on patients with ≥30% blasts. We analyzed 55 newly diagnosed AML patients, treated with azacitidine. The
Rena Buckstein et al.
Cancer treatment reviews, 37(2), 160-167 (2010-07-02)
Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoiesis that results in peripheral blood cytopenias and a marked propensity to progress to acute myelogenous leukemia. With 40,000-76,000 new cases per year in the USA, MDS is the commonest of the

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service